Hamartia Antidote
Elite Member
Cancer became undetectable on scans in one in 12 of the patients given daraxonrasib along with chemotherapy in early medical trials.

RASONQUE (AKA Daraxonrasib) by Revolution Medicines (Redwood City, California)
Daraxonrasib (RASONQUE™) FDA Approved: How It Targets RAS in Pancreatic Cancer | MOA


This is the key hero guy:
Gregory Verdine | HSCRB
Gregory Verdine is a pioneer in the field of chemical biology, a serial biotech entrepreneur and a life science venture capitalist. In an independent academic career at Harvard University and Harvard Medical School spanning nearly 3 decades, he has elucidated the molecular mechanism of epigenetic DNA methylation and the pathways by which certain genotoxic forms of DNA damage are surveilled in and eradicated from the genome. He is a leading figure in the field of new therapeutic modalities, and has developed a new class of therapeutics termed stapled peptides, which are currently in clinical development and have received much attention for their ability to drug targets previously considered “undruggable.” Dr. Verdine is Erving Professor of Chemistry in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology.
Last edited:
